Global Thrombolysis Market: Research & Forecast 2018-2023 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 29, 2018--The “Global Thrombolysis Market Research and Forecast 2018-2023” report has been added to ResearchAndMarkets.com’s offering.
The thrombolysis market is expected to grow significantly during the forecast period (2018-2023).
The global thrombolysis market is influenced by the various factors which include growing incidence and prevalence of blood related diseases such as deep vein thrombosis, pulmonary embolism, strokes, and heart attack. There are favorable reimbursement policies that are driving the market.
Increasing geriatric population and obesity is the main cause of clotting which lead to the growth of the market. Thrombolysis is considered as the emergency medical service to dissolve the blood clots from the arteries that feed the heart and the brain. This advantage of thrombolysis helps for the growth of the market.
Rising awareness through promotional initiatives and campaigns across the globe, rising healthcare expenditure, technological advancement and excessive collaborations between market players create the future opportunity for the growth of the market.
Although there are various factors which hinders the growth of the market such as side effects of the treatment, high cost of the medicines and treatment, and lack of healthcare infrastructure in low economic countries.
Considering the regional outlook, the market is divided into North America, Europe, Asia Pacific and Rest of the world. North America rules the market with the highest incidence of deep vein thrombosis. In addition, there are advanced technologies and developed healthcare infrastructure in the region that propels the growth in North America.
Europe stands second in the race due to high rate of diagnosis and treatment, ability of introducing new innovation by investing in research and development, and presence of good healthcare facilities.
APAC is anticipated to capture a significant market share in the coming years due to rising consciousness among people, developing technology and healthcare amenities and large number of patient pool.
There are various companies contributing to the global Thrombolysis market with their products and services. Some of them are Eumedica Pharmaceuticals, Genentech Inc., SEDICO Co., Taj Pharmaceuticals, ND Pharma, Angiocare, Straub medicals, Mochida Pharmaceuticals Co. Ltd., ivascular, Syner- Med Ltd., and Teleflex Incorporation.
With the technological advancement these companies are coming with new innovation and techniques with improved products and services in order to provide best possible treatment.
Key Topics Covered
1. Report Summary
1.1. Research Methods And Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview And Insights
2.2. Analyst Insights &Current Market Trends
2.2.1. Key Findings
2.3.1. United States
2.3.2. European Union
2.3.5. Rest Of The World
3. Market Determinant
3.1.1. Growing Incidence And Prevalence Of Blood Related Diseases
3.1.2. Favourable Reimbursement Policies
3.1.3. Increasing Obesity Coupled With Geriatric Population
3.1.4. Technological Advancement
3.2.1. Side Effects Of The Treatment
3.2.2. Lack Of Health Infrastructure In Low Economic Countries
3.2.3. High Cost Of Medicines.
3.3.1. Promotional Initiatives And Campaigns To Raise Awareness
3.3.2. Increasing Healthcare Spending
3.3.3. Extensive Collaborations Between Market Players
4. Market Segmentation
4.1. By Drug Types
4.1.1. Fibrin Specific Drug
4.1.2. Non- Fibrin Specific Drug
4.2. By Application
4.2.1. Deep Vein Thrombosis
4.2.2. Acute Ischemic Strokes
4.2.3. Pulmonary Embolism
4.2.4. Acute Myocardial
4.2.5. Blocked Catheters
4.3. By End User
4.3.2. Ambulatory Surgical Centres
5. Competitive Landscape
5.1. Key Market Strategies
5.2. Key Company Analysis
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.3. Rest Of North America
6.2.1. United Kingdom
6.2.6. Rest Of Europe
6.3. Asia Pacific
6.4. Rest Of The World
7. Company Profiles
7.1. Angiocare Bv
7.2. Angiodynamics, Inc.
7.3. Argon Medical Devices Inc.
7.4. Athersys, Inc.
7.5. Bayer AG
7.6. Boehringer Ingelheim Gmbh
7.7. Boston Scientific Corporation
7.8. Bristol-Myers Squibb
7.9. BTG Plc
7.10. Ekos Corporation
7.11. Genentech Inc.
7.12. Glaxosmithkline Plc
7.13. Ivascular S.L.U
7.14. Lemaitre Vascular, Inc.
7.15. Medtronic Plc
7.16. Microbix Biosystems Inc.
7.17. Penumbra Inc
7.18. Portola Pharmaceuticals, Inc.
7.19. South Egypt Drug Industries Co.
7.20. Straub Medical AG
7.21. Teleflex Inc.
7.22. Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/rtpg24/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181129005651/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/29/2018 12:59 PM/DISC: 11/29/2018 12:59 PM